NCT00398047 · OUTCOME

Change in Bone Marrow Apoptosis

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes · Source last updated 2018-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline and approximately 12 months

Analysis population: Because no patients completed therapy, no analysis was done

Groups in this outcome

Azacitidine and Darbopoietin and G-CSF

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Azacitidine and Darbopoietin and G-CSF	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

id
OG000
title
Azacitidine and Darbopoietin and G-CSF

population Description

Because no patients completed therapy, no analysis was done

reporting Status

POSTED

time Frame

Baseline and approximately 12 months

title

Change in Bone Marrow Apoptosis

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice